Navigation Links
New fusion gene plays role in some stomach cancers
Date:4/6/2011

DURHAM, N.C. A newly discovered hybrid gene appears to play a direct role in some stomach cancers, according to an international team of scientists led by researchers at Duke-NUS Graduate Medical School Singapore.

The hybrid gene is a fusion of two separate genes, and is one of the first described in gastric cancer, which is the most lethal malignancy worldwide after lung cancer. The disease kills an estimated 740,000 people a year, including nearly 11,000 annually in the United States.

The gene discovery may one day give doctors a more effective way to use current therapies, plus help researchers develop new drugs and diagnostic tools for gastric cancer.

"This is an extremely exciting area, as it opens up a potential role for fusion genes in solid cancer diagnostics and treatment, similar to the fundamental role they have played in the blood cancers," said Dr. Patrick Tan, associate professor in the Cancer and Stem Cell Biology Program at the Duke-NUS Graduate Medical School Singapore. Tan was principal investigator of the study published in the April 6, 2011, issue of the journal Science Translational Medicine.

Tan said the research team -- which also included scientists from the National University of Singapore, National Cancer Centre of Singapore, the Genome Institute of Singapore, Yonsei University College of Medicine in Seoul, South Korea, and Howard University -- used a novel genomic approach to isolate the fusion gene.

The technology is called genomic breakpoint analysis (GBA), which has been used to identify fusion genes in leukemia, but has had less success in pinpointing them in complex solid tumors.

By using the technology to home in on abnormal genes in 133 stomach cancer tumors and cell lines, the Singapore-based research group found evidence of a single genetic error that was common to four of the cancer samples.

Finding the error led the scientists to the CD44-SLC1A2 fusion gene, which resulted when two nearby genes blended into one. The SLC1A2 gene is associated with the metabolism of the amino acid glutamate, which can work like a fertilizer encouraging tumor growth and survival, while the CD44 gene serves as a sort of "on" switch.

Melded into one, the CD44-SLC1A2 hybrid appears to fuel stomach tumors. Tan's team estimates the fusion gene may be at work in up to 2 percent of stomach cancers.

"Using high-throughput genomic technologies such as sequencing and GBA, we are now finding that cancers do express many fusion genes," Tan said. "The current feeling is that while most of these are harmless and 'noise' from genomic instability, there can be cases, such as CD44-SLC1A2, where the fusion gene contributes actively to the cancer."

The finding could lead to improved therapies for this subset of stomach cancers. As part of the study, the researchers used a gene silencing approach to reduce the levels of CD44-SLC1A2 in cancer cell lines. They found that this caused a reduction in the glutamate levels of cancer cells, and made the cells more vulnerable to the effects of cisplatin, a common chemotherapy.

"It does suggest that drugs that inhibit SLC1A2 function could be used to sensitize tumors to chemotherapy," Tan said. "Such glutamate uptake inhibitors are available, and we are working very hard to test this possibility."


'/>"/>

Contact: Sarah Avery
sarah.avery@duke.edu
919-660-1306
Duke University Medical Center
Source:Eurekalert

Related medicine news :

1. Low-Dose Platelet Transfusions Deemed Safe
2. Sunquest Information Systems Enters into Business Relationship with MedFusion of Dallas
3. Complex Technologies Announces Partnership with 6fusion to Deliver Cloud Services
4. FDA Targets Safety Problems With Infusion Drug Pumps
5. FusionLab Designs Thomson Reuters iPad Application Interface for Financial Professionals, Students and Market Enthusiasts
6. Healthcare Reform Confusion May Create Coverage Gap for College Graduates
7. CareFusion Newport Jazz Festival Discounts Tickets for Health Care Practitioners
8. NHLBI funds research to improve safety of red blood cell transfusions
9. Study describes health effects of occupational exposures in Paducah Gaseous Diffusion Plant workers
10. Mammogram Guidelines Still Beget Confusion
11. Reducing blood transfusions improves patient safety and cuts costs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... bible in homes across the world. Yisrayl says this generation is a time like no ... to turn to the Bible. , Yisrayl says he does not want to sound like ...
(Date:1/20/2017)... ... January 20, 2017 , ... Bionic Sports Nutrition LLC, an American company devoted ... had a successful January ECRM Trade Show in Hilton Head, SC. , Bionic ... it to provide its products to all clients at reasonable prices. At the ECRM ...
(Date:1/20/2017)... Raton, FL (PRWEB) , ... January 20, 2017 , ... ... level of nutritional and bodybuilding supplements, announced it attended the January ECRM trade show ... respected bodybuilder and nutritional scientist who was determined to create a line of products ...
(Date:1/20/2017)... ... January 20, 2017 , ... Vitamin Well has ... 002. The drinks have been produced in collaboration with Zlatan Ibrahimovic and have ... workout. , After a successful launch in Sweden last year, the next generation ...
(Date:1/20/2017)... ... ... Chocolate Biscuit”: a biographical account following a man who went on to support his country ... Ivey, born in Lynn Haven, Florida and at the age of 5, his family moved ... he joined the Navy and got married right out of boot camp. , He ...
Breaking Medicine News(10 mins):
(Date:1/20/2017)... DUBAI , VAE, January 20, 2017 ... den stark gestiegenen Bedarf an Nothilfe   Die ... um Platz für Hilfsgüter zu schaffen   ... Vizepräsident und Premierminister der VAE sowie Herrscher von ... Umfang der internationalen Stadt der Hilfe (International Humanitarian City ...
(Date:1/19/2017)... NEW YORK , Jan. 19, 2017 /PRNewswire/ ... reach USD 233.7 billion by 2025, according to ... The market is anticipated to be predominantly driven ... companies, resulting into the large-scale production of new ... widen the influx of drugs at an unprecedented ...
(Date:1/19/2017)... Jan. 19, 2017 The U.S. Food and Drug ... Idiopathic Constipation (CIC) in adult patients. "No ... disorders," said Julie Beitz , M.D., director of the ... Drug Evaluation and Research. "With the availability of new therapies, ... for their condition." ...
Breaking Medicine Technology: